BiotechTube

Epetraborole

Phase 1Completed
1 views this week 0 watching💤 Quiet
Interest: 19/100
19
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Renal Insufficiency

Conditions

Renal Insufficiency

Trial Timeline

Feb 21, 2022 → Jun 27, 2022

NCT ID
NCT05283746

About Epetraborole

Epetraborole is a phase 1 stage product being developed by AN2 Therapeutics for Renal Insufficiency. The current trial status is completed. This product is registered under clinical trial identifier NCT05283746. Target conditions include Renal Insufficiency.

What happened to similar drugs?

20 of 20 similar drugs in Renal Insufficiency were approved

Approved (20) Terminated (0) Active (0)
✅tacrolimus + CellCept + steroids (methylprednisone or prednisone)Astellas PharmaApproved
✅Rituximab + Tacrolimus + Mycophenylate mofetil + Hydrocortisone + Prednisolone + PrednisoloneAstellas PharmaApproved
✅Tacrolimus, Prograf®Astellas PharmaApproved
✅Astagraf XL + Prograf + Mycophenolate mofetilAstellas PharmaApproved
✅Tacrolimus - Prograf® twice daily formulation + Tacrolimus - Advagraf® once daily formulationAstellas PharmaApproved
✅Tacrolimus + CyclosporineAstellas PharmaApproved
✅Tacrolimus sustained-release capsuleAstellas PharmaApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05283746Phase 1Completed

Competing Products

20 competing products in Renal Insufficiency

See all competitors
ProductCompanyStageHype Score
MBX 2109 + MBX 2109 + MBX 2109 + MBX 2109MBX BiosciencesPhase 1
23
LY3473329Eli LillyPhase 1
29
Tildacerfont/PlaceboSpruce BiosciencesPhase 2
17
SPR001Spruce BiosciencesPhase 2
25
SPR001Spruce BiosciencesPhase 2
25
Tildacerfont/PlaceboSpruce BiosciencesPhase 2
17
TildacerfontSpruce BiosciencesPhase 2
17
Drotrecogin alfa activated (Xigris)Eli LillyPhase 2
35
LY3819469Eli LillyPhase 1
29
Atezolizumab + CabozantinibChugai PharmaceuticalPhase 3
32
DS-6000a + DS-6000aDaiichi SankyoPhase 1
33
DS-1093aDaiichi SankyoPhase 1
29
CS-3150Daiichi SankyoPhase 3
40
AGS-16C3FAstellas PharmaPhase 1
29
AGS-16M8FAstellas PharmaPhase 1
29
CP-461Astellas PharmaPhase 2
35
roxadustatAstellas PharmaPhase 3
40
YM178Astellas PharmaPhase 1
29
intravenous immunoglobulins (IVIG)Astellas PharmaPhase 1
29
bixalomerAstellas PharmaPre-clinical
26